Lang et al. (2019) evaluated the utility of UDCA in patients with tuberculosis (TBC) and DILI [defined as an increase in alanine aminotransferase (ALT) > 5 upper limit of normal (ULN), alkaline phosphatase (ALP) > 2 ULN or TBL> 2ULN] due to anti-TBC drugs in a prospective study but uncontrolled design. The gene discussed is GPT; the disease is tuberculosis.